XML 16 R2.htm IDEA: XBRL DOCUMENT v3.21.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Current Assets:    
Cash and cash equivalents $ 351,163 $ 383,928
Accounts receivable, net 381,792 331,429
Inventories 225,559 209,873
Other current assets 139,284 137,508
Total current assets 1,097,798 1,062,738
Long-Term Assets:    
Property and equipment, net 543,963 555,167
Operating lease right-of-use assets 93,565 91,171
Goodwill 242,586 243,347
Intangible assets, net 53,969 52,543
Other long-term assets 295,504 289,595
Total long-term assets 1,229,587 1,231,823
TOTAL ASSETS 2,327,385 2,294,561
Current Liabilities:    
Accounts payable 87,175 74,558
Accrued liabilities 366,877 415,648
Current portion of long-term debt 124,971 49,988
Current portion of deferred revenue 41,639 42,567
Total current liabilities 620,662 582,761
Long-Term Liabilities:    
Deferred income tax liabilities 18,566 11,707
Long-term debt, net of current portion 778,747 858,492
Long-term deferred revenue, net of current portion 44,233 46,163
Long-term operating lease liabilities 78,193 77,039
Other long-term liabilities 83,549 85,604
Total long-term liabilities 1,003,288 1,079,005
Total liabilities 1,623,950 1,661,766
Commitments and Contingencies (Note 15)
Stockholders’ Equity:    
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued:106,676 shares in 2021 and 106,457 shares in 2020; Outstanding: 85,365 shares in 2021 and 85,449 shares in 2020 10,668 10,646
Additional paid-in capital 1,321,086 1,294,849
Deferred stock units: Outstanding: 87 units in 2021 and 87 units in 2020 4,549 4,503
Retained earnings 2,379,852 2,175,595
Accumulated other comprehensive loss (59,536) (53,615)
Treasury stock, at cost: 21,311 shares in 2021 and 21,008 shares in 2020 (2,953,923) (2,799,890)
Total IDEXX Laboratories, Inc. stockholders’ equity 702,696 632,088
Noncontrolling interest 739 707
Total stockholders’ equity 703,435 632,795
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 2,327,385 $ 2,294,561